Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
29
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Steroidal farnesoid X receptor (FXR) agonists demonstrated potent anti-fibrotic activities and lowered portal hypertension in experimental models. The impact of the novel non-steroidal and selective FXR agonist PX20606 on portal hypertension and fibrosis was explored in this study.

          Related collections

          Author and article information

          Journal
          J. Hepatol.
          Journal of hepatology
          Elsevier BV
          1600-0641
          0168-8278
          Apr 2017
          : 66
          : 4
          Affiliations
          [1 ] Div. of Gastroenterology and Hepatology, Dept. of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
          [2 ] Phenex Pharmaceuticals, Waldhofer Strasse 104, 69123 Heidelberg, Germany.
          [3 ] Vienna Medical Innovation Center (VMIC), Group Practice LABORS.at, Vienna, Austria.
          [4 ] Synovo GmbH, Paul-Ehrlich-Str. 15, 72076 Tübingen, Germany.
          [5 ] Dept. of Surgery, Medical University of Vienna, Vienna, Austria.
          [6 ] Dept. of Pathology, Medical University of Vienna, Vienna, Austria.
          [7 ] Dept. of Biomedical Research, Medical University of Vienna, Vienna, Austria.
          [8 ] Div. of Gastroenterology and Hepatology, Dept. of Internal Medicine III, Medical University of Vienna, Vienna, Austria. Electronic address: michael.trauner@meduniwien.ac.at.
          Article
          S0168-8278(16)30710-3
          10.1016/j.jhep.2016.12.005
          27993716
          1cc6a485-25d2-4b41-a080-6f694d964dcf
          History

          Bacterial translocation,Cirrhosis,FXR agonist,Farnesoid X receptor,Fibrosis,Intestinal permeability,Mouse,PX20606,Portal hypertension,Rat

          Comments

          Comment on this article